Mexiletine Uses
Mexiletine is FDA-approved for life-threatening ventricular arrhythmias (sustained ventricular tachycardia), but has important off-label uses in neuropathic pain conditions and specific cardiac channelopathies. 1
Primary FDA-Approved Indication
Life-Threatening Ventricular Arrhythmias
Mexiletine is indicated for documented ventricular arrhythmias, specifically sustained ventricular tachycardia, that are life-threatening. 1 The FDA label explicitly states that use for lesser arrhythmias is not recommended, and treatment of asymptomatic ventricular premature contractions should be avoided. 1 Importantly, antiarrhythmic drugs including mexiletine have not been shown to enhance survival in patients with ventricular arrhythmias. 1
Cardiac Uses Beyond Primary Indication
Refractory Ventricular Tachycardia/Ventricular Fibrillation
In patients with structural heart disease and recurrent VT/VF refractory to first-line therapies (sotalol, amiodarone, or catheter ablation), mexiletine should be given in addition to amiodarone, not as monotherapy. 2 The 2020 Canadian guidelines emphasize that mexiletine has limited efficacy as monotherapy and must be combined with amiodarone. 2
A critical caveat: A pre-ICD era randomized trial showed increased mortality when mexiletine was used in patients with heart failure, so it should be used with caution in this population. 2
Hypertrophic Cardiomyopathy with Ventricular Arrhythmias
The 2020 AHA/ACC guidelines recommend mexiletine as one of several antiarrhythmic options for adults with HCM and symptomatic ventricular arrhythmias or recurrent ICD shocks despite beta-blocker use. 3, 4 However, the guidelines note that proof of efficacy for mexiletine is scant and it is often used adjunctively to amiodarone. 3, 4
Long QT Syndrome Type 3 (LQT3)
Mexiletine provides genotype-specific treatment for LQT3 patients, shortening the QTc interval and reducing recurrent arrhythmias. 5 This represents a first-line, targeted therapy for this specific genetic subtype. 5 The 2006 ACC/AHA/ESC guidelines also mention mexiletine may be considered for patients with LQT3 presenting with torsades de pointes. 6
Neuropathic Pain Conditions
Painful Diabetic Peripheral Neuropathy
Mexiletine has been used for diabetic neuropathy, though evidence is modest. A 2011 consensus guideline notes that mexiletine provides only modest analgesic effect and requires regular ECG monitoring, so long-term use cannot be recommended. 7 Multiple randomized trials showed variable results, with only some demonstrating statistically significant pain reduction compared to placebo. 8
Erythromelalgia
For erythromelalgia (particularly primary EM with SCN9A mutations affecting Nav1.7 sodium channels), mexiletine serves as a safer oral alternative to intravenous lidocaine. 9 The 2023 Mayo Clinic review emphasizes that mexiletine is much safer than IV lidocaine infusions, which carry risks of neurologic effects like slurred speech and altered mental status. 9
General Neuropathic Pain
A 2020 geriatrics guideline states that given the lack of evidence and side-effect profiles that may be problematic in older adults, oral mexiletine and similar antiarrhythmics are not favored for general neuropathic pain management. 10
Key Safety Considerations
- Initiation must occur in hospital for life-threatening arrhythmias 1
- ECG monitoring is necessary due to potential proarrhythmic effects 7, 1
- Hepatic metabolism: Dose adjustment needed in liver disease; elimination half-life is prolonged with hepatic impairment 1
- Common adverse effects: Gastrointestinal complaints (especially nausea) in ~33% of patients, neurologic symptoms (dizziness, tremor), and rarely seizures (2 per 1000 patients) 1
- Drug interactions: CYP2D6 and CYP1A2 substrate; interacts with fluvoxamine, propafenone, phenytoin, rifampin, theophylline, and caffeine 1
- Contraindicated in second or third-degree heart block unless a pacemaker is present 1
Practical Dosing Context
While specific dosing wasn't requested, the evidence shows typical doses range from 150-300 mg/day for mexiletine monotherapy, with combination therapy (mexiletine + amiodarone) using similar ranges. 7, 9, 8 The 2022 systematic review found that higher mexiletine dosages correlate with increased side effects (r² = 0.48; P=0.014). 11